Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rolapitant Dose 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Rolapitant Dose 1 | EXPERIMENTAL | - |
| Rolapitant Dose 2 | EXPERIMENTAL | - |
| Rolapitant Dose 3 | EXPERIMENTAL | - |
| Rolapitant Dose 4 | EXPERIMENTAL | - |
| Ondansetron | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Rolapitant Dose 1 | DRUG | Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1 |
| Rolapitant Dose 2 | DRUG | Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1 |
| Rolapitant Dose 3 | DRUG | Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1 |
| Rolapitant Dose 4 | DRUG | 200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1 |
| Ondansetron | DRUG | Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1 |
| Placebo | DRUG | Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1 |
Inclusion Criteria: * Women aged 18 years or older of any race with an American Society of Anesthesiologists (ASA) physical status of I to III who are scheduled to undergo elective open abdominal surgery under general anesthesia. * Women whose postoperative hospitalization is expected to last at le...
Rolapitant Dose 1 is an investigational small molecule being studied for the prevention of postoperative nausea and vomiting (PONV) in female patients aged 18 years and older. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Rolapitant Dose 1 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 2 clinical development for postoperative nausea and vomiting.
Rolapitant Dose 1 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for the prevention of postoperative nausea and vomiting in adult female patients.
Rolapitant Dose 1 has one completed Phase 2 clinical trial, identified as NCT00539721. This randomized, double-blind, placebo-controlled study enrolled 619 female participants aged 18 years and older to evaluate the drug for the prevention of postoperative nausea and vomiting following surgery.
Rolapitant Dose 1 is a specific dose formulation of the drug rolapitant. The clinical trial NCT00539721 evaluates this particular dose for the prevention of postoperative nausea and vomiting. The drug is being developed by Merck & Company, Inc. under the ticker MRK.